Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Palisade Bio Inc (PALI)

Palisade Bio Inc (PALI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 268,205
  • Shares Outstanding, K 149,003
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,440 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 1.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 74.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +98.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6500 +9.70%
on 12/03/25
2.4500 -26.12%
on 11/20/25
+0.1300 (+7.74%)
since 11/07/25
3-Month
0.5300 +241.51%
on 09/11/25
2.4500 -26.12%
on 11/20/25
+1.2391 (+217.04%)
since 09/08/25
52-Week
0.5300 +241.51%
on 09/11/25
3.3000 -45.15%
on 12/12/24
+0.0400 (+2.26%)
since 12/06/24

Most Recent Stories

More News
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02,...

PALI : 1.8100 (+0.56%)
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Live webcast fireside chat on Thursday, December 4 th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”),...

PALI : 1.8100 (+0.56%)
PALISADES ANNOUNCES EXTENSION OF CONVERTIBLE NOTE

VANCOUVER, BC , Nov. 11, 2025 /CNW/ - Palisades Goldcorp Ltd.  (TSXV: PALI) (" Palisades " or the "Company ") announced today that further to its May 21, 2025 news release, the Company...

PALI : 1.8100 (+0.56%)
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on...

PALI : 1.8100 (+0.56%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI)

NEW YORK , Oct. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Palisade Bio, Inc. (NASDAQ: PALI) on behalf of the company's shareholders. The investigation seeks...

PALI : 1.8100 (+0.56%)
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances...

PALI : 1.8100 (+0.56%)
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs...

PALI : 1.8100 (+0.56%)
Palisade Bio Cancels Stockholder Meeting Due to Quorum

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Palisade...

PALI : 1.8100 (+0.56%)
Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel...

PALI : 1.8100 (+0.56%)
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Offering was led by B Group Capital and Columbia Threadneedle Investments with significant participation from Adage Capital Partners LP, ADAR1 Capital Management, Boxer Capital Management, Coastlands...

PALI : 1.8100 (+0.56%)

Business Summary

Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 1.9400
2nd Resistance Point 1.8900
1st Resistance Point 1.8500
Last Price 1.8100
1st Support Level 1.7600
2nd Support Level 1.7100
3rd Support Level 1.6700

See More

52-Week High 3.3000
Fibonacci 61.8% 2.2419
Fibonacci 50% 1.9150
Last Price 1.8100
Fibonacci 38.2% 1.5881
52-Week Low 0.5300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar